Article

Cytotoxic Phenylpropanoids and a New Triterpene, Turformosinic Acid, from *Turpinia formosana* Nakai

Hui-Chi Huang [1,†], Chun-Tang Chiou [2,†], Ping-Chun Hsiao [2], Chia-Ching Liaw [2], Li-Jie Zhang [2], Chao-Lin Chang [2], Ih-Sheng Chen [3], Wen-Chi Chen [4], Kuo-Hsiung Lee [5,6] and Yao-Haur Kuo [2,4,*]

[1] School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources,
China Medical University, Taichung 404, Taiwan

[2] Division of Herbal Drug and Natural Products, National Research Institute of Chinese Medicine,
Taipei 112, Taiwan

[3] College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan

[4] Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University,
Taichung 404, Taiwan

[5] Natural Products Research Laboratories, UNC Eshelman School of Pharmacy,
University of North Carolina, Chapel Hill, NC 27599, USA

[6] Chinese Medicine Research and Development Center, China Medical University and Hospital,
Taichung 404, Taiwan

[†] These authors contribute equally to this work.

[*] Author to whom correspondence should be addressed; E-Mail: kuoyh@nricm.edu.tw;
Tel.: +886-2-2820-1999 ext. 7061; Fax: +886-2-2823-6150.

Abstract: One new phenylpropanoid, turformosin A (**1**), and one new triterpene, turformosinic acid (**2**), together with 16 known compounds, were isolated from the stems of *Turpinia formosana* Nakai. All structures were elucidated on the basis of spectroscopic analysis, including 1D- and 2D-NMR techniques and MS analysis. Selected isolated compounds were evaluated for *in vitro* cytotoxicity against four human cancer cell lines and antioxidant scavenging effects on DPPH. (−)-(7′*S*,8′*S*)-*threo*-carolignan X (**3**) exhibited cytotoxicity against Hep2, WiDr, Daoy, and MCF-7 cell lines with ED_{50} values of 3.60, 4.45, 6.07, and 13.7 μg/mL, respectively. Turformosin A (**1**), (−)-(7′*S*,8′*S*)-*threo*-carolignan X (**3**), methoxyhydroquinone-4-β-D-glucopyranoside (**5**), and methoxy-hydroquinone-1-β-D-glucopyranoside (**6**), exhibited similar anti-oxidative activity. Hep2

cells treated with 10 μg/mL of **3** showed elevation of sub-G1 population (from 20% at 8 h to 60% at 48 h), and activation of caspase-9/caspase-3/PARP cascade. Compound **3** induced intrinsic apoptotic pathway in Hep2 cells with dose and time dependence (10 μg/mL for 8 h).

1. Introduction

Turpinia formosana Nakai (Staphyleaceae) is an endemic plant which is widely found in the southern Taiwanese mountains. The roots have been used in Taiwanese traditional medicine to activate blood circulation, reduce swelling, and relieve pain and splenomegaly [1]. The genus *Turpinia* contains ten species found in subtropical and tropical Asia and America [2]. In previous pharmaceutical investigations on crude extracts of *Turpinia* sp., *T. pomifera* showed antimalarial activity against *Plasmodium falciparum* [3], and *T. ternate* demonstrated cytotoxicity against *Artemia salina* larvae as well as antioxidant activity [4]. Other Staphyleaceous plants, including *Staphylea pinnata* and *Stephanandra tanakae*, exhibited anti-bacterial [5] and cytotoxic [6] effects, respectively. Previous phytochemical studies showed that plants from this family contain ellegic acid derivatives [4], megastigmans [7], megastigman glycosides [8–10], flavonol glycosides, anthocyanins [11], amino acid amides, and triterpenoic acids [12].

In our continuing search for anticancer principles from Taiwanese plants, we found that an EtOH extract of the stems of *T. formosana* Nakai showed cytotoxic activity against the Hep2 and Daoy cell lines. However, no detailed reports are available concerning the chemistry and pharmacological activities of this plant. Our subsequent phytochemical analysis of the EtOH extract has led to the isolation of a new phenylpropanoid, turformosin A (**1**), and a new oleanane-type triterpene, turformosinic acid (**2**), as well as 16 known compounds (**3–18**) (Figure 1).

**Figure 1.** Chemical structure of compounds **1–18** from *T. formosana* Nakai.


	R₁	R₂	R₃
1	α-OH	OCH₃	H
3	β-OH	H	OCH₃

	R₁	R₂	R₃	R₄
2	=O	H	H	CH₂OH
4	H	α-OH	β-OH	CH₃

Figure 1. *Cont.*

5 R$_1$=OH, R$_2$=OCH$_3$, R$_3$=H, R$_4$=H

6 R$_1$=OH, R$_2$=H, R$_3$=OCH$_3$, R$_4$=H

7 R$_1$=CH$_2$OH, R$_2$=H, R$_3$=OCH$_3$, R$_4$=OCH$_3$

8 R$_1$=CH=CHCH$_2$OH, R$_2$=H, R$_3$=OCH$_3$, R$_4$=OCH$_3$

9 R=H

10 R=OCH$_3$

11 R=H

12 R=OCH$_3$

13

14 R= Xyl

15 R= Rha

16

17

18

The structures of the two new compounds were elucidated by extensive spectroscopic methods including 1D- and 2D-NMR experiments. Selected isolated compounds (**1**–**6** and **9**–**16**) were also evaluated for cytotoxic and antioxidative activities. (−)-(7′*S*,8′*S*)-*threo*-Carolignan X (**3**) [13] showed strong cytotoxicity against Hep2 cells. In addition, this is the first report on the cytotoxic activities of (−)-(7′*S*,8′*S*)-*threo*-carolignan X (**3**) and induced apoptosis in Hep2 cells is also described.

2. Results and Discussion

2.1. Structure Determination

Compound **1** was isolated as a colorless amorphous solid. A sodiated ion peak at *m/z* 723.2420 ([M+Na]$^+$; calc. 723.2417) in the HR-ESI-MS of **1** was consistent with the molecular formula C$_{39}$H$_{40}$O$_{12}$. The UV absorption maxima (λ_{max} = 229, 289, and 317 nm) indicated the presence of aromatic moieties. The IR absorption bands of **1** were characteristic for hydroxy (ν_{max} = 3,398 cm^{-1}), carbonyl (ν_{max} = 1,687 cm^{-1}), and aromatic ring (ν_{max} = 1,603 and 1,508 cm^{-1}) moieties. The ^{1}H-NMR spectrum

of **1** (Table 1) showed four sets of phenyl signals with one A_2B_2 and three ABX coupled systems at δ_H 6.64 ~ 7.32. One ABX set of aromatic signals at δ_H 6.76 (H-5), 6.88 (H-6), and 7.07 (H-2), together with three oxygenated protons at δ_H 4.45 (2H, m, H-9), 4.60 (1H, m, H-8), 4.92 (1H, d, J = 5.5 Hz, H-7), as well as a methoxy group [δ_H 3.79 (3H, s, OCH$_3$)], suggested the presence of a (4-hydroxy-3-methoxyphenyl)-7,8,9-propantriol moiety in the molecule [14]. A second ABX-type coupling system consisted of three aromatic proton signals at δ_H 6.64 (H-5'), 6.73 (H-2') and 6.84 (H-6'). Based on HMBC correlations (Figure 2), this phenyl ring was substituted with a methoxy group [δ_H 3.72 (s)] and a propanol unit [δ_H 1.89 (2H, t, J = 7.0 Hz, H-8'), 2.59 (2H, dd, J = 7.5, 7.0 Hz, H-7'), and 4.09 (2H, d, J = 6.0 Hz, H-9')]. Thus, the second aromatic unit was established as a (4-hydroxy-3-methoxyphenyl)-9'-propanol system [14]. A third phenylpropanoid unit was assigned as a feruloyl unit, based on the presence of characteristic signals for an aromatic moiety with an ABX pattern system [δ_H 7.13 (1H, s, H-2"), 7.02 (1H, d, J = 8.0 Hz, H-6") and 6.80 (1H, d, J = 8.0, H-5")], a methoxy group (δ_H 3.84), a pair of *trans*-vinyl groups [δ_H = 7.56 (1H, d, J = 16.0, H-7") and 6.32 (1H, d, J = 16.0, H-8")], and an ester carbonyl carbon [δ_C 169.3 (C-9")] [15]. The remaining aromatic signals showed an A_2B_2 coupling pattern [δ_H 7.32 (2H, d, J = 8.0 Hz, H-2''' and 6''') and 6.78 (2H, m, H-3''' and 5''')] linked to a pair of *trans*-vinyl protons [δ_H 7.36 (1H, d, J = 16.0 Hz, H-7''') and 6.14 (1H, d, J = 16.0 Hz, H-8''')], and an ester carbonyl carbon [δ_C 168.9 (C-9''')]. The fourth aromatic system was therefore identified as a 4'''-hydroxycinnamoyl unit.

Table 1. ^{1}H-NMR and ^{13}C-NMR spectroscopic data (δ in ppm, J in Hz) of compound **1**.

Position	δ_H [a]	δ_C [b]	δ_C [c]	Position	δ_H [a]	δ_C [b]	δ_C [c]
1	-	133.8	131.0	1"	-	127.6	126.7
2	7.07 (s)	111.6	108.9	2"	7.13 (s)	111.7	109.4
3	-	148.7	146.8	3"	-	150.5	146.6
4	-	146.9	145.1	4"	-	149.2	148.1
5	6.76 (d, J = 8.0)	115.8	114.2	5"	6.80 (d, J = 8.0)	116.4	115.0
6	6.88 (d, J = 8.0)	120.8	119.3	6"	7.02 (d, J = 8.0)	124.1	123.1
7	4.92 (d, J = 5.5)	74.1	72.3	7"	7.56 (d, J = 16.0)	146.6	145.2
8	4.60 (m)	83.7	84.2	8"	6.32 (d, J = 16.0)	115.5	115.1
9	4.45 (m)	64.8	62.8	9"	-	169.3	167.6
MeO-3	3.79 (s)	56.4	55.8	MeO-3"	3.84 (s)	56.4	55.9
1'	-	137.5	137.2	1'''	-	127.0	126.5
2'	6.73 (s)	113.9	112.4	2'''	7.32 (d, J = 8.0)	131.2	130.0
3'	-	151.9	151.1	3'''	6.78 (m)	116.8	115.9
4'	-	147.2	145.0	4'''	-	161.1	158.4
5'	6.64 (d, J = 7.5)	121.7	120.4	5'''	6.78 (m)	116.8	115.9
6'	6.84 (d, J = 7.5)	119.7	121.1	6'''	7.32 (d, J = 8.0)	131.2	130.0
7'	2.59 (dd, J = 7.5, 7.0)	32.8	31.9	7'''	7.36 (d, J = 16.0)	146.7	145.2
8'	1.89 (t, J = 7.0)	31.4	30.3	8'''	6.14 (d, J = 16.0)	114.9	114.5
9'	4.09 (t, J = 6.0)	64.8	63.8	9'''	-	168.9	164.4
OMe-3'	3.72 (s)	56.4	55.8				

[a] 500 MHz for ^{1}H-NMR in CD$_3$OD; [b] 125 MHz for ^{13}C-NMR in CD$_3$OD; [c] 125 MHz for ^{13}C-NMR in CDCl$_3$.

Moreover, the assignments for the four phenylpropanoid units based on the above proton NMR data were also supported by appropriate carbon signals in the ^{13}C-NMR (Table 1) and HMQC spectra of **1**.

Compound **1** is thus closely related to (−)-(7'*S*,8'*S*)-*threo*-carolignan X (**3**), except for the position of feruloyl and 4-hydroxycinnamoyl units and the stereochemistry of the 7,8,9-propantriol moiety [13]. Inspection of the HMBC spectrum of **1** revealed cross peaks between the following proton and carbon signals: H-8 (δ_H 4.60) with C-4' (phenoxy ring δ_C 147.2), H-9 (δ_H 4.45) with C-9" (δ_C 169.3, carbonyl carbon in ferulic acid), and H-9' (δ_H 4.09) with C-9''' (δ_C 168.9, cinnamic acid carbonyl), which determined the planar structure of **1** to be 7-(4-hydroxy-3-methoxyphenyl)-9-(4-hydroxy-3-methoxy-cinnamoyloxy)-8{4'-[9'-(4-hydroxycinnamoyloxy)-7'-propenyl]-3'-methoxyphenoxy}-1-propanol. Due to the presence of two chiral carbons in the 7,8,9-trioxygenated propane moiety of **1**, two possible diastereomers (*erythro* and *threo*) are possible for **1**. Comparison of the chemical shift and coupling constant data of H-7 and H-8 with **3** and **1** indicated that **1** belongs to the *erythro* series [15,16]. When the ^{1}H-NMR spectrum of **1** and **3** was measured in CDCl$_3$ instead of CD$_3$OD, the coupling constants for H-7 were clearly observed. Therefore, we also use the CDCl$_3$ to analyze the ^{1}H- and ^{13}C-NMR of **1** and **3**. The proton resonance of H-7 in compound **3** appeared as a doublet and higher coupling constant (J_{H7-H8} = 8.0 Hz) determined the *threo* diastereomer, which was further deduced to possess a *trans* diaxial orientation. As to compound **1**, the H-7 proton resonance had a small coupling constant (J_{H7-H8} = 3.2 Hz), indicating the presence of the *erythro* diastereomer. Comparison of the ^{13}C spectra (CDCl$_3$) of **1** and **3**, compound **1** has higher field C-7 signals (δ_C 72.3 in **1**; δ_C 74.4 in **3**), C-8 (δ_C 84.2 in **1**; δ_C 86.2 in **3**), and C-9 (δ_C 62.8 in **1**; δ_C 63.1 in **3**) revealing the *erythro* form of **1**, rather than the *threo* form of **3** [13]. Therefore, *erythro*-**1** have the (7*R*,8*S*) configuration and *threo*-**3** would be 7S,8S configuration. Based on the above data, **1** was elucidated as *erythro*-7-(4-hydroxy-3-methoxyphenyl)-9-(4-hydroxy-3-methoxycinnamoyloxy)-8{4'-[9'-(4-hydroxycinnamoyloxy)-7'-propenyl]-3'-methoxyphenoxy}-1-propanol and has been named as turformosin A.

Compound **2** was obtained as a colorless amorphous solid. A molecular ion peak at *m/z* 502.3290 [M]$^+$ in the HR-ESI-MS spectrum suggested its molecular formula to be C$_{30}$H$_{46}$O$_6$ (calculated mass: *m/z* 502.3294). The ^{1}H-NMR spectrum (Table 2) revealed the presence of five methyl groups [δ_H = 1.33, 1.19, 0.92, 0.87, and 0.86 (each 3H, s)], two hydroxymethylene groups at δ_H 3.48 and 3.33 (each 1H, d, *J* = 11.2 Hz), 3.19 (2H, br s), one olefinic proton [δ_H 5.24 (1H, t-like, *J* = 4.0 Hz)], and an oxygen-bearing methine at δ_H 3.81 (1H, dd, *J* = 12.0, 4.8 Hz). The ^{13}C-NMR (Table 2) and DEPT spectra of **2** showed 30 carbon signals including five methyls, eleven methylenes, five methines, seven quaternary carbons and two carbonyl carbons. Signals for olefinic proton at δ_H 5.24 and two olefinic carbons at δ_H 124.0 (C-12) and 144.4 (C-13), are indicative of an olen-12-en [17]. The ^{13}C NMR data for rings B-D of **2** were similar to those of **4**. However, the ^{13}C NMR spectrum of **2** showed the presence of signals for a carbonyl moiety (δ_C 215.0). The carbonyl group was assigned at C-1 (δ_C 215.0), resulting in a deshielding effect on C-2 and C-10 (*ca.* δ_C 25.0 and 14.0, respectively), as compared to **4**.

Table 2. ^{1}H-NMR and ^{13}C-NMR spectroscopic data ^{a} (δ in ppm, J in Hz) of compound **2** in CD$_3$OD.

			2		
Position	δ_H ^{b}	δ_C ^{c}	Position	δ_H ^{b}	δ_C ^{c}
1	-	215.0	16	1.99 (dd, J = 13.2, 3.2)	24.0
				1.60 (m)	
2	2.29 (dd, J = 12.0, 5.2)	44.6	17	-	48.0
	3.10 (t, J = 12.0)				
3	3.81 (dd, J = 12.0, 4.8)	73.3	18	2.88 (dd, J = 13.6, 4.0)	42.1
4	-	44.0	19	1.80 (m), 1.09 (m)	41.0
5	1.35 (m)	47.6	20	-	36.7
6	1.56 (m)	18.4	21	1.25 (d, J = 8.8)	33.0
				1.76 (m)	
7	1.27 (dd, J = 10.0, 3.2)	33.2	22	1.14 (m)	29.2
	1.58 m			1.47 (m)	
8	-	40.3	23	3.48 (d, J = 11.2)	65.8
				3.33 (d, J = 11.2)	
9	2.25 (dd, J = 10.4, 5.6)	40.2	24	0.86 (s)	13.2
10	-	53.2	25	1.33 (s)	15.9
11	2.27 (m), 1.83 (m)	26.2	26	0.87 (s)	18.3
12	5.24 (t-like, J = 4.0)	124.0	27	1.19 (s)	26.3
13	-	144.4	28	-	181.7
14	-	43.1	29	3.19 (br s)	74.3
15	1.74 (m), 1.06 (m)	28.7	30	0.92 (s)	19.5

^{a} Assignments made using the HSQC and HMBC techniques; ^{b} 400 MHz for ^{1}H-NMR; ^{c} 100 MHz for ^{13}C-NMR.

The HMBC spectrum (Figure 2) of **2** showed correlations between the oxymethine proton signal at δ_H 3.81 (H-3) and the carbon signals at δ_C 44.6 (C-2), 44.0 (C-4), and 13.2 (C-24). From the coupling constant of H-3 (J = 12.0, 4.8), the hydroxy group at C-3 was assigned as having a β-orientation [18].

Figure 2. Key HMBC (arrow) and ^{1}H-^{1}H COSY (bold lines) correlations of compounds **1**–**2**.

HMBC correlations between the proton at δ_H = 3.48 and carbons at δ_C 13.2 (C-24), 44.0 (C-4), and 47.6 (C-5), between δ_H 3.33 and δ_C 13.2 (C-24) and 44.0 (C-4), and between δ_H 3.19 and δ_c 41.0 (C-19), 36.7 (C-20), 33.0 (C-21) and 19.5 (C-30), suggested that the two secondary hydroxy groups were connected to C-23 and C-29, respectively.

The cross-peaks between C-1 (δ_C 215.0) and H-2a (δ_H 2.29), H-2b (δ_H 3.10), and Me-25 (δ_H 1.33) in the HMBC spectrum also agreed with this assignment. The complete ^{1}H- and ^{13}C-NMR spectroscopic assignments were established by the analyses of ^{1}H-^{1}H COSY, HMQC and HMBC data. The relative stereochemistry was determined by its MM2-minimized energy-calculated molecular model drawing with NOESY correlations (Figure 3). The NOESY spectrum showed the correlations of Me-25/H-2b, Me-24 and Me-26, H-3/H-2a, H-5 and H$_2$-23, as well as H-9/H-5 and Me-27, suggesting that 3-OH, Me-24, Me-25, and Me-26 were all in β-orientation. On the basis of the above evidence, the structure of **2** was established as 3β,23,29-trihydroxy-1-oxo-olean-12-en-28-oic acid, and **2** has been given the name turformosinic acid.

Figure 3. (**A**) Key NOESY (curve) correlations of compound **2**; (**B**) Computer-generated perspective model of **2** using MM2 force field calculation.

A   **B**

The 16 additional isolated compounds were identified as (−)-(7′*S*,8′*S*)-*threo*-carolignan X (**3**) [13], 2α,3β,19β-23-tetrahydroxyolean-12-en-28-oic acid (**4**) [17], methoxyhydroquinone-4-β-D-glucopyranoside (**5**) [19], methoxyhydroquinone-1-β-D-glucopyranoside (**6**) [20], 3,5-dimethoxybenzyl alcohol 4-*O*-β-D-glucopyranoside (**7**) [21], 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl β-D-glucopyranoside (**8**) [22], D-*threo*-guaiacylglycerol-*O*-β-D-glucopyranoside (**9**) [23], (7*S*,8*R*)-syringoylglycerol-7-*O*-β-D-glucopyranoside (**10**) [24], 6-*O*-(*p*-hydroxybenzoyl)-D-glucose (**11**) [25], D-glucose-6(4-hydroxy-3-methoxybenzoate) (**12**) [26], dihydrophaseic acid 4′-*O*-β-D-glucopyranoside (**13**) [27], 3′-*O*-methyl ellagic acid 4-*O*-β-D-xylopyranoside (**14**) [28], 3′-*O*-methyl ellagic acid 4-*O*-α-L-rhamnopyranoside (**15**) [29], uridine (**16**) [30], adenosine (**17**) [31], and β-sitosteryl glucoside (**18**) [32], respectively, by comparison with the spectroscopic data reported in the literature for these compounds.

2.2. Cytotoxicity and DHHP Radical Scavenging Activity

Most of isolated compounds (**1–6** and **9–16**; >1.0 mg), except for compounds **7** and **8** due to their limited amounts (<1.0 mg), were evaluated for cytotoxicity against human tumor cell lines (Hep2, WiDr, Daoy, and MCF-7) and antioxidant scavenging effects on DPPH (Table 3), using mitomycin C and α-tocopherol as positive controls, respectively. Compound **3** showed ED$_{50}$ values of 3.60, 4.45, 6.07, and 13.69 μg/mL against Hep2, WiDr, Daoy, and MCF-7 cell lines, respectively, whereas **1** exhibited much lower ED$_{50}$ values of 13.22, 12.07, and 11.46 μg/mL against the Hep2, WiDr, and Daoy cell lines, respectively. In addition, **1**, **3**, **5**, and **6** exhibited significant antioxidant effects with IC$_{50}$ values of 26.9, 28.4, 23.6, and 30.8 μg/mL, respectively. Compounds **2**, **4**, and **9–16** showed neither cytotoxic nor anti-oxidative activity.

Table 3. Cytotoxicity and antioxidant scavenging effects of compounds **1**–**6** and **9**–**16**.

Compound	Anti-oxidative [a]	Cytotoxicity [b]			
	DPPH test	MCF-7	Daoy	WiDr	Hep2
	ED$_{50}$ (µg/mL)	ED$_{50}$ (µg/mL)			
1	26.9	- [c]	11.46	12.07	13.22
3	28.4	13.69	6.07	4.45	3.60
5	23.6	-	-	-	-
6	30.8	-	-	-	-
Positive control	12.25 [d]	0.15 [e]	0.08 [e]	0.15 [e]	0.16 [e]

[a] Compounds **2**, **4**, and **9**–**16** were inactive; [b] Compounds **2**, **4** and **9**–**16** were inactive (ED$_{50}$ > 20 µg/mL); [c] (-): inactive; [d] Positive control: α-tocopherol. [e] Positive control: Mitomycin C.

Figure 4. Mechanism of compound **3**-induced cell death.

(**A**) Compound **3** increased the portion of subG1 in the cell cycle analysis. Cells were treated with **3** and harvested at the indicated time points. Cells were fixed with 70% alcohol, stained with propidium iodide, and analyzed by flow cytometry. Three independent experiments were performed and the portion of subG1 was presented as mean ± standard deviations. The group of cells treated with 10 µM of doxorubicin (Dox) for 48 h is shown as the positive control; (**B**) Compound **3** induced cytochrome *c* release in Hep2 cells. The mitochondrial and cytosolic fractions were separated by SDS-PAGE, then transferred to PVDF membrane, and analyzed by Western blotting. Hsp60 and tubulin are the marker proteins of mitochondria and cytosol, respectively; (**C**) Compound **3** induced apoptosis in Hep2 cells. Cells treated with or without **3** were harvested at the indicated time points and lyzed with the RIPA buffer for lysates preparation. The lysates were separated by SDS-PAGE, then transferred to PVDF membrane, and analyzed by Western blotting.

2.3. Cell Cycle Analysis and Immunobloting

To investigate how **3** affects cell viability, we performed a cell cycle analysis. Hep2 cells treated with 10 μg/mL of **3** showed an elevating subG1 population (from 20% at 8 h to 60% at 48 h), but no difference in vehicle nor 5 μg/mL of **3** (Figure 4A). Compound **3**-induced apoptosis was determined by Western blotting. The cytosolic cytochrome c increased from 8 h to 24 h in the 10 μg/mL **3**-treated cells (Figure 4B). Furthermore, levels of procaspase-9, procaspase-3, and Bcl-2 were reduced in **3**-treated cells (Figure 4C). Then, caspase-3 mediated cleavage of PARP was also found (Figure 4C). Taken together, these results suggest that compound **3** triggers apoptosis through the intrinsic apoptosis pathway.

3. Experimental

3.1. General

The optical rotations were measured using a JASCO DIP-370 digital polarimeter. Infrared (IR) spectra were measured on a Mattson Genesis II spectrophotometer using a KBr matrix. UV spectra were measured a Hitachi U-3200 spectrophotometer. EI-MS were measured with JEOL Finnigan MAT TSQ-46C and JEOL SX-102A mass spectrometers. High-resolution mass spectra (HR-MS) were recorded by ESI MS on JEOL JMS-700 MStation and Hewlett-Packard 5989B mass spectrometers. ^{1}H and ^{13}C NMR spectra were obtained using Bruker Avance DRX 500 MHz and Bruker Avance 400 MHz spectrometers with tetramethylsilane (TMS) as the internal standard. Two-dimensional (2D) NMR experiments (HMQC, HMBC, and ROESY) were conducted using Bruker Avance DRX-500 and Bruker Avance 400 spectrometers. Sephadex LH-20 (Lipophilic Sephadex; Amersham Biosciences, Ltd.) and silica gel (230–400 mesh; Merck & Co., Inc.) were used for column chromatography, and pre-coated silica gel (60 F-254; Merck & Co., Inc.) plates were used for TLC. The spots on TLC were detected by spraying with 5% H_2SO_4 and then heating at 100 °C. Preparative HPLC was performed using a reverse phase column (Cosmosil 5SL-II column, 250 mm × 20 mm i.d.; Nacalai Tesque, Inc.) on a Shimadzu LC-6AD series apparatus with RID-10A refractive index and Prominence HPLC UV-Vis detectors.

3.2. Plant Material

The stems of *T. formosana* Nakai were collected in Ping-Tung County, Taiwan, in May, 2007. This material was identified by one of the authors (I.-S. Chen). A voucher specimen (code No. KTF200705A) has been deposited at the National Research Institute of Chinese Medicine, Taipei, Taiwan.

3.3. Extraction and Isolation

The dried stems of *T. formosana* Nakai (10.5 kg) were extracted two times with 95% EtOH (2 × 60 L). The EtOH extract was dried under reduced pressure at 45 °C to yield a brown syrup (*ca.* 650 g). The concentrated extract was subsequently partitioned successively with EtOAc (4 L × 4) and *n*-BuOH (4 L × 3) to afford 95 and 110 g, respectively. The EtOAc-soluble portion was subjected to flash chromatography on a silica gel column (60 × 300 mm), using CHCl$_3$-MeOH (stepwise, 100:0 to 0:100,

10 L) to afford ten fractions (F-1 ~ F-10). Fraction 3 (F-3) was chromatographed over silica gel (30 × 200 mm) with *n*-hexane/EtOAc (40:1 ~ 0:1) to give four sub-fractions (F-3-1 ~ F-3-4). S ub-fraction (F-3-2) was purified over Sephadex LH-20 (20 × 900 mm) using CH_2Cl_2-MeOH (1:1, 500 mL) to produce six sub-fractions (F-3-2-1 ~ F-3-2-6). Sub-fraction (F-3-2-3) was purified by RP-HPLC (Cosmosil 5C[18]-AR-II column, 250 × 20 mm i.d.) using 65% CH_3OH to yield **1** (16.5 mg) and **2** (12.8 mg). Fraction 9 (F-9) was chromatographed over silica gel (30 × 200 mm) with CH_2Cl_2/MeOH (50:1 ~ 0:1) to give ten sub-fractions (F-9-1 ~ F-9-10). Sub-fraction (F-9-1) was purified over Sephadex LH-20 (20 × 900 mm) using CH_2Cl_2-MeOH (1:1, 500 mL) to produce six sub-fractions (F-9-1-1 ~ F-9-1-6). Sub-fraction (F-9-1-5) was purified by RP-HPLC (Cosmosil 5C[18]-AR-II column, 250 × 20 mm i.d.) using 75% CH_3OH to yield **3** (1.2 mg) and **4** (4.9 mg).

The *n*-butanol extract was further chromatographed on silica gel (40 × 300 mm) using an increasing gradient of MeOH in CH_2Cl_2 to obtain six fractions (F-1 ~ F-6). Fraction (F-4) was subjected to Sephadex LH-20 column (20 × 900 mm) chromatography eluted with MeOH (300 mL) to afford five sub-fractions (F-4-1 ~ F-4-5). Sub-fraction (F-4-1) was purified by preparative HPLC (Cosmosil 5C[18]-AR-II, 250 × 20 mm i.d., 65% MeOH) to give **5** (2.2 mg), **6** (3.1 mg), **7** (0.9 mg), **8** (0.6 mg) and **9** (5.6 mg). Sub-fraction (F-4-2) (3.72 g) was rechromatographed over a Sephadex LH-20 column (20 × 900 mm) using CH_2Cl_2-MeOH (1:4, 300 mL) to give four sub-fractions (F-4-2-1 ~ F-4-2-4). Sub-fraction (F-4-2-3) (1.02 g) was fractionated over a reversed phase preparative HPLC (Cosmosil 5C[18]-AR-II column, 250 × 20 mm i.d., 50% MeOH) to afford **10** (1.2 mg), and **13** (6.8 mg). Compounds **14** (8.1 mg), **15** (2.1 mg), and **16** (1.7 mg) were purified from sub-fraction (F-4-2-4) (1.02 g) by PTLC using CH_2Cl_2/MeOH (6:1). Sub-fraction (F-4-3) (340 mg) was chromatographed on Sephadex LH-20 (20 × 900 mm) using MeOH (400 mL) to yield four sub-fractions (F-4-3-1 ~ F-4-3-4). Employing a reversed phase preparative HPLC (Cosmosil 5C[18]-AR-II column, 250 × 20 mm i.d., 45% MeOH), **17** (3.2 mg) and **18** (28.3 mg) were obtained from sub-fraction (F-4-3-2) (50 mg). Sub-fraction (F-4-3-4) was further purified by RP-HPLC (Cosmosil 5C[18]-AR-II column, 250 × 20 mm i.d.) using 65% MeOH to furnish **11** (14.7 mg) and **12** (49.8 mg). The purity of the isolated compounds ranged from 97.0% to 99.5% as assessed by analytical HPLC (Cosmosil 5C[18]-AR-II column, 250 × 4.6 mm i.d., 45% MeOH, UV detection, 254 and 210 nm, flow rate: 1.0 mL/min).

3.4. Spectral Data

Turformosin A (**1**)*:* colorless amorphous solid; $[\alpha]_D^{25}$: +16.6 (*c* 0.2, MeOH); UV (MeOH) λ_{max} (log ε) 229 (4.25), 289 (4.13), 317 (4.30) nm; IR (neat) v_{max} 3,398, 2,938, 2,839, 1,687, 1,631, 1,603, 1,508 cm^{-1}; HR-ESI-MS *m/z* 723.2420 $[M+Na]^+$ (calcd. for $C_{39}H_{40}O_{12}Na$, 723.2417); ^{1}H- and ^{13}C-NMR data, see Table 1.

Turformosinic acid (**2**): colorless amorphous solid; $[\alpha]_D^{25}$: +122.3 (*c* 0.1, MeOH); IR (neat) v_{max} 3,384, 2,938, 2,868, 1,566, 1,550, 1,376, 1,048; HR-ESI-MS *m/z* 502.3290 $[M]^+$ (calcd. for $C_{30}H_{46}O_6$, 502.3294); ^{1}H- and ^{13}C-NMR data, see Table 2.

3.5. Cytotoxicity Assay

Cytotoxicity against Hep2 (human laryngeal carcinoma), WiDr *(*human colon adenocarcinoma), Daoy (human medulloblastoma), and MCF-7 (human breast adenocarcinoma) cells was measured using a 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, based on reported methods [33]. Briefly, the cells were cultured in RPMI-1640 medium supplemented with serum in an atmosphere of 5% CO_2 incubated at 37 °C. Test samples and the control drug standard were prepared at concentrations of 1, 10, 20, and 40 μg/mL. After seeding 2,880 cells/well in a 96-well microplate for 4 h, 20 μL of sample or standard agent was placed in each well and incubated at 37 °C for 3 days. Twenty μL of MTT were added, and incubation continued for 5 h. After removing the medium and adding DMSO (200 μL/well) into the microplate with shaking for 10 min, the formazan crystals (the product of MTT reacting with dehydrogenase existing in mitochondria) were re-dissolved, and their absorbance was measured on a model MR 7000 microtiter plate reader (Dynatech International Corporation, Edgewood, New York, NY, USA) at a wavelength of 550 nm. The ED_{50} was defined as the concentration of test sample resulting in 50% reduction of the absorbance found with the untreated cells.

3.6. DPPH Radical Scavenging Activity

The stable 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical was used for the determination of free radical-scavenging activity of the extracts and compounds. Test compounds (**1–6**, **9–16**, and **18**) (120 μL) were added to 30 μL of DPPH (0.75 mM). After 30 min at room temperature, the absorbance was recorded at 520 nm. The experiment was repeated three times. Radical-scavenging activity (%) was calculated by the following formula: $\{[Ab − (A − As)]/Ab\} × 100$, where Ab is the absorbance without sample, A is the absorbance with compound and DPPH, and As is the absorbance with compound only [34]. If the activity of the test compound was more than 70%, the ED_{50} value was calculated.

3.7. Cell Cycle and DNA Content Analysis

Cells were seeded in a 6-cm dish and cultured overnight. Cells were incubated with fresh medium containing compound **3**. At the indicated time points, attached cells were trypsinized and combined with those in the supernatant. Cells were fixed with 70% EtOH at −20 °C and treated with 0.1% Triton X-100 for 30 min at room temperature. Then, cells were incubated with 50 μg/mL of RNase A and 50 μg/mL of propidium iodide (Sigma, St. Louis, MO, USA) in PBS at room temperature for 15 min. The relative proportions of cells in the G_1, S, and G_2/M cell-cycle phases were estimated by compartment analysis of DNA fluorescence using fluorescence-activated cell sorter (FACS) flow cytometry (Becton Dickinson, San Jose, CA, USA). Data were analyzed using the CellQuest software (Verity Software House Inc., Topsham, ME, USA).

3.8. Preparation of Mitochondrial and Cytosolic Fractions

After being cultured overnight, cells were incubated with fresh medium containing compound **2**. At the indicated time points, cells were trypsinized and washed twice with ice-cold PBS. Cells were

resuspended in ice-cold extraction buffer [20 mM HEPES, pH 7.4, 10 mM KCl, 250 mM sucrose, 1.5 mM MgCl$_2$, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1× protease inhibitor cocktail (Merck)] and incubated for 10 min at 4 °C. Cells were homogenized with 15 strokes of a prechilled homogenizer, and the homogenates were sequentially centrifuged at 1,000 × g and 12,000 × g for 5 and 30 min, respectively, at 4 °C. The supernatant was collected as the cytosolic fraction. The pellet was re-suspended with ice-cold lysis buffer [20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1 mM dithiothreitol, 1× protease inhibitor cocktail (Merck)] and incubated for 20 min at 4 °C. The lysates were centrifuged at 15,000 × g for 5 min, and the supernatant was collected as the mitochondrial fraction.

3.9. Immunoblotting

Samples were separated by SDS-PAGE and transferred to PVDF sheets. Membranes were blocked with 5% non-fat milk dissolved in PBST buffer [137 mM NaCl, 3 mM KCl, 10 mM Na$_2$HPO$_4$, 2 mM KH$_2$PO$_4$, 0.1% (v/v) Tween-20] for 1 h and incubated with the primary antibody at 4 °C overnight. Then, membranes were washed thoroughly with PBST buffer and incubated for 1 h with the secondary antibody at room temperature. Immunoreactive protein was visualized using Immobilon western chemiluminescent HRP substrate according to the manufacturer's protocol (Millipore, Billerica, MA, USA). Antibodies against Bcl-2, Bcl-xL, and Bax were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against caspase-9 and PARP were obtained from BD Pharmingen (San Diego, CA, USA). The anti-caspase-3 antibody was purchased from Millipore (Billerica, MA, USA). Horse radish peroxidase (HRP)-conjugated anti-mouse IgG and HRP-conjugated anti-rabbit IgG were obtained from Jackson ImmunoResearch, Inc. (West Grove, PA, USA).

4. Conclusions

The EtOH extract of *T. formosana* Nakai was partitioned successively with EtOAc and *n*-BuOH. The EtOAc portion was fractionated by column chromatography on Sephadex LH-20 and silica gel, as well as separated by HPLC, to afford one new phenylpropanoid, turformosin A (**1**), one new triterpenoid, turformosinic acid (**2**), and two known compounds, (−)-(7′*S*,8′*S*)-*threo*-carolignan X (**3**) and 2α,3β,19β-23-tetrahydroxy-olean-12-en-28-oic acid (**4**). From the *n*-BuOH layer, fourteen known compounds, methoxyhydroquinone-4-β-D-glucopyranoside (**5**), methoxyhydroquinone-1-β-D-gluco-pyranoside (**6**), 3,5-dimethoxybenzyl alcohol 4-*O*-β-D-glucopyranoside (**7**), 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl β-D-glucopyranoside (**8**), D-*threo*-guaiacylglycerol-*O*-β-D-glucopyranoside (**9**), (7*S*,8*R*)-syringoylglycerol-7-*O*-β-D-glucopyranoside (**10**), 6-*O*-(*p*-hydroxybenzoyl)-D-glucose (**11**), D-glucose-6(4-hydroxy-3-methoxybenzoate) (**12**), dihydrophaseic acid 4′-*O*-β-D-glucopyranoside (**13**), 3′-*O*-methyl ellagic acid 4-*O*-β-D-xylopyranoside (**14**), 3-*O*-methylellagic acid 4-*O*-α-L-rhamnopyranoside (**15**), uridine (**16**), adenosine (**17**), and β-sitosteryl-3-*O*-β-D-glucopyranoside (**18**), were obtained. Their structures were determined based on extensive spectroscopic analyses, especially 2D NMR (^{1}H-^{1}H COSY, HMQC, HMBC, and NOESY) as well as HRMS. On the antioxidation screening effects on DPPH for the isolated compounds, compounds **1**, **3**, **5**, and **6** showed significant antioxidant effects. On the other hand, compound **3** exhibited most potent cytotoxicity against WiDr and Hep2 cancer cell lins with IC$_{50}$ of 4.45 and 3.60 μg/mL, respectively. Compound **3** modulates

intrinsic apoptotic pathway proteins in Hep2 cells, as shown by change expression of Bcl-2 family. In addition, compound **3** triggers caspase activation and also induces the release of cytochrome *c* and activation of caspase-9/caspase-3/PARP cascade.

Acknowledgements

References and Notes

1. *The Catalogue of Medicinal Plant Resources in Taiwan*; Hanasty Printing Co. Ltd.: Taipei, Taiwan, 2003; p. 298.
2. Li, H.L. *Flora of Taiwan*, 2nd ed.; Editorial Committee of the Flora of Taiwan: Taipei, Taiwan, 2003; Volume 3, p. 663.
3. Horgen, F.D.; Edrada, R.A.; de los Reyes, G.; Agcaoili, F.; Madulid, D.A.; Wongpanich, V.; Angerhofer, C.K.; Pezzuto, J.M.; Soejarto, D.D.; Farnsworth, N.R. Biological screening of rain forest plot trees fro*m Palawan Island* (Philippines). *Phytomedicine* **2001**, *8*, 71–81.
4. Matthew, S.; Kao, K.C.; Chang, Y.S.; Abreu, P. Ellagic acid glycosides from *Turpinia ternata*. *Nat. Prod. Res.* **2007**, *21*, 83–88.
5. Jantova, S.; Nagy, M.; Ruzeková, L.; Grancai, D. Antibacterial activity of plant extracts from the families Fabaceae, Oleaceae, Philadelphaceae, Rosaceae and Staphyleaceae. *Phytother. Res.* **2000**, *14*, 601–603.
6. Jantova, S.; Nagy, M.; Ruzeková, L.; Grancai, D. Cytotoxic effects of plant extracts from the families Fabaceae, Oleaceae, Philadelphaceae, Rosaceae and Staphyleaceae. *Phytother. Res.* **2001**, *15*, 22–25.
7. Takeda, Y.; Okada, Y.; Masuda, T.; Hirata, E.; Shinzato, T.; Takushi, A.; Yu, Q.; Otsuka, H. New megastigmane and tetraketide from the leaves of *Euscaphis japonica*. *Chem. Pharm. Bull.* **2000**, *48*, 752–754.
8. Yu, Q.; Otsuka, H.; Hirata, E.; Shinzato, T.; Takeda, Y. Turpinionosides A–E: Megastigmane glucosides from leaves of *Turpinia ternate* Nakai. *Chem. Pharm. Bull.* **2002**, *50*, 640–644.
9. Yu, Q.; Matsunami, K.; Otsuka, H.; Takeda, Y. Staphylionosides A–K: Megastigmane glucosides from the leaves of *Staphylea bumalda* DC. *Chem. Pharm. Bull.* **2005**, *53*, 800–807.
10. Nakanish, T.; Iida, N.; Inatomi, Y.; Murata, H.; Inada, A.; Murata, J.; Lang, F.A.; Iinuma, M.; Tanaka, T.; Sakagami, Y. A monoterpene glucoside and three megastigmane glycosides from *Juniperus communis* var. *depressa*. *Chem. Pharm. Bull.* **2005**, *53*, 783–787.
11. Takeda, Y.; Okada, Y.; Masuda, T.; Hirata, E.; Takushi, A.; Otsuka, H. Euscapholide and its glucoside from leaves of *Euscaphis japonica*. *Phytochemistry* **1998**, *49*, 2565–2658.
12. Konishi, T.; Otani, T.; Kiyosawa, S.; Fujiwara, Y. Constituents of the capsules of *Euscaphis japonica* (THUNB.) KANTIZ. *Chem. Pharm. Bull.* **1996**, *44*, 863–864.

13. Rudiyansyah; Lambert, L.K.; Garson, M.J. Lignans and triterpenes from the bark of *Durio carinatus* and *Durio oxleyanus*. *J. Nat. Prod.* **2010**, *73*, 1649–1654.

14. Wu, P.L.; Chuang, T.H.; He, C.X.; Wu, T.S. Bioassay-guided isolation and cytotoxicity of phenylpropanoid esters from the stems of *Hibiscus taiwanensis*. *Bioorg. Med. Chem.* **2004**, *12*, 2193–2197.

15. Shimomura, H.; Sashida, Y.; Oohara, M. Lignans from *Machilus thunbergii*. *Phytochemistry* **1987**, *26*, 1513–1515.

16. Seca, A.M.; Silva, A.M.; Silvestre, A.J.; Cavaleiro, J.A.; Domingues, F.M.; Pascoal-Neto, C. Phenolic constituents from the core of Kenaf (*Hibiscus cannabinus*). *Phytochemistry* **2001**, *56*, 759–767.

17. Jossang, A.; Seuleiman, M.; Maidou, E.; Bodo, B. Pentacyclic triterpenes from *Combretum nigricans*. *Phytochemistry* **1996**, *41*, 591–594.

18. Okada, Y.; Omae, A.; Okuyama, T. A new triterpenoid isolated from *Lagerstronemia speciosa* (L.) Pers. *Chem. Pharm. Bull.* **2003**, *51*, 452–454.

19. Wangensteen, H.; Miron, A.; Alamgir, M.; Rajia, S.; Samuelsen, A.B.; Malterud, K.E. Antioxidant and 15-lipoxygenase inhibitory activity of rotenoids, isoflavones and phenolic glycosides from *Sarcolobus globosus*. *Fitoterapia* **2006**, *77*, 290–295.

20. Inoshiri, S.; Sasaki, M.; Kohda, H.; Otsuka, H.; Yamasaki, K. Aromatic glycosides from *Berchemia racemosa*. *Phytochemistry* **1987**, *26*, 2811–2814.

21. Park, K.M.; Yang, M.C.; Lee, K.H.; Kim, K.R.; Choi, S.U.; Lee, K.R. Cytotoxic phenolic constituents of *Acer tegmentosum* Maxim. *Arch. Pharm. Res.* **2006**, *29*, 1086–1090.

22. Dübeler, A.; Voltmer, G.; Gora, V.; Lunderstädt, J.; Zeeck, A. Phenols from *Fagus sylvatica* and their role in defence against *Cryptococcus fagisuga*. *Phytochemistry* **1997**, *45*, 51–57.

23. Sugiyama, M.; Kikuchi, M. Studies on the constituents of *Osmanthus Species*. X. Structures of phenolic glucosides from the leaves of *Osmanthus asiaticus* Nakai. *Chem. Pharm. Bull.* **1992**, *40*, 325–326.

24. Ouyang, M.A.; Kuo, Y.H. Water-soluble constituents from aerial roots of *Ficus microcarpa*. *J. Asian Nat. Prod.* **2006**, *8*, 625–630.

25. Kaneko, T.; Ohtani, K.; Kasai, R.; Yamasaki, K.; Duc, N.M. *n*-Alkyl glycosides and *p*-hydroxybenzoyloxy glucose from fruits of *Crescentia cujete*. *Phytochemistry* **1998**, *47*, 259–263.

26. Ding, H.Y.; Wu, Y.C.; Lin, H.C.; Chan, Y.Y.; Wu, P.L.; Wu, T.S. Glycosides from *Paeonia suffruticosa*. *Chem. Pharm. Bull.* **1999**, *47*, 652–655.

27. Champavier, Y.; Comte, G.; Vercauteren, J.; Allais, D.P.; Chulia, A.J. Norterpenoid and sesquiterpenoid glucosides from *Juniperus phynicea* and *Galega officinalis*. *Phytochemistry* **1999**, *50*, 1219–1223.

28. Khallouki, F.; Haubner, R.; Huall, W.E.; Erben, G.; Spiegelhalder, B.; Bartsch, H.; Owen, R.W. Isolation, purification and identification of ellagic acid derivatives, catechins, and procyanidins from the root bark of *Anisophyllea dichostyla* R. Br. *Food. Chem. Toxic* **2007**, *45*, 472–485.

29. Hillis, W.E.; Yazaki, Y. Properties of some methylellagic acids and their glycosides. *Phytochemistry* **1973**, *12*, 2963–2968.